Levomilnacipran (Fetzima): A New SNRI for Depression
December 23, 2013 (Issue: 1432)
The FDA has approved levomilnacipran (lee" voe mil
na' si pran; Fetzima – Forest), a serotonin and norepinephrine
reuptake inhibitor (SNRI), for treatment of
major depressive disorder. Levomilnacipran is the
more active enantiomer of...more
1. Milnacipran (Savella) for fibromyalgia. Med Lett Drugs Ther 2009; 51:45.
2. Drugs for psychiatric disorders. Treat Guidel Med Lett 2013; 11:53.
3. AL Auclair et al. Levomilnacipran (F2695), a norepinephrine-preferring SNRI: profile in vitro and in models of depression and anxiety. Neuropharmacology 2013; 70:338.
4. GM Asnis et al. Efficacy and safety of levomilnacipran sustained release 40 mg, 80 mg, or 120 mg in major depressive disorder: a phase 3 randomized, double-blind, placebo-controlled study. J Clin Psychiatry 2013; 74:242.
5. D Bakish et al. Levomilnacipran ER 40 mg and 80 mg in patients with major depressive disorder: a phase III, randomized, double-blind, fixed-dose, placebo-controlled study. J Psychiatry Neurosci 2013 October 22 (epub).
6. A Sambunaris et al. A phase III, double-blind, placebo-controlled, flexible-dose study of levomilnacipran extended-release in patients with major depressive disorder. J Clin Psychopharmacol 2013 November 27 (epub).
7. R Mago et al. Safety and tolerability of levomilnacipran ER in major depressive disorder: results from an open-label, 48-week extension study. Clin Drug Investig 2013; 33:761.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.
Would you like to read the rest of this issue? Gain access below.
Subscribe
Subscriptions to
The Medical Letter on Drugs and Therapeutics include:
- Print version published and mailed biweekly (26 issues/year)
- Unlimited online access to current and past issues (1988 - present)
- Mobile App
- FREE online per issue CME/CE
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
